Luitpold Pharmaceuticals announced it changed its legal name to American Regent, Inc. effective January 2, 2019. The name change follows consolidation of two subsidiaries into Luitpold to streamline operations. Until this announcement, American Regent was the market facing brand for Luitpold's iron products and multisource injectable franchise, which represented more than 95% of 2017 revenue.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
"Our goal under this renaming is to work together as one company, under one brand and with one purpose," said Ken Keller, President and CEO of American Regent, "which is to support patient health. Nothing is more important than the safety and quality of our products and the patients they treat."
With its exclusively U.S.-based manufacturing platform, the company is positioning itself to quickly mobilize resources, more rapidly respond to market shortages, and invest in more complex sterile manufacturing. It is further investing in manufacturing facilities to provide additional flexibility in production scheduling and to drive speedier responses to changes in market demand.
"This transition represents a major milestone, which includes investing in a shorter supply chain, evolving toward more complex injectable products, and more quickly delivering against the immediate needs of U.S. hospitals and clinics," said Harsher Singh, American Regent Vice President and Chief Commercial Officer, of the company's future growth and transition. "The name American Regent reinforces our commitment to achieving greater heights as a reliable, responsive, and respected partner."